CRISPR Therapeutics AG (NASDAQ:CRSP – Get Rating) – Equities researchers at Zacks Research issued their Q3 2022 earnings per share estimates for CRISPR Therapeutics in a report released on Wednesday, September 14th. Zacks Research analyst S. Ganoria anticipates that the company will earn ($2.44) per share for the quarter. The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($9.26) per share. Zacks Research also issued estimates for CRISPR Therapeutics’ Q4 2022 earnings at ($2.37) EPS, FY2022 earnings at ($9.53) EPS, Q1 2023 earnings at ($2.40) EPS, Q2 2023 earnings at ($2.37) EPS, Q3 2023 earnings at ($2.48) EPS, Q4 2023 earnings at ($0.07) EPS, FY2023 earnings at ($7.31) EPS, Q1 2024 earnings at ($2.22) EPS, Q2 2024 earnings at ($1.97) EPS and FY2024 earnings at ($7.50) EPS.
Several other equities research analysts have also recently weighed in on the company. Credit Suisse Group increased their price objective on CRISPR Therapeutics from $74.00 to $90.00 and gave the company a “neutral” rating in a research report on Tuesday, August 9th. Oppenheimer reduced their price objective on CRISPR Therapeutics from $150.00 to $122.00 and set an “outperform” rating for the company in a research report on Thursday, June 23rd. TheStreet lowered CRISPR Therapeutics from a “c” rating to a “d” rating in a research note on Thursday, August 18th. Chardan Capital cut their target price on CRISPR Therapeutics from $164.00 to $154.00 and set a “buy” rating for the company in a research note on Tuesday, August 9th. Finally, Barclays lowered CRISPR Therapeutics from an “overweight” rating to an “equal weight” rating and cut their target price for the company from $99.00 to $88.00 in a research note on Tuesday, August 9th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat.com, CRISPR Therapeutics has a consensus rating of “Hold” and a consensus target price of $112.33.
CRISPR Therapeutics Trading Down 6.0 %
CRSP opened at $70.53 on Monday. CRISPR Therapeutics has a 1-year low of $42.51 and a 1-year high of $124.79. The stock has a market capitalization of $5.50 billion, a price-to-earnings ratio of -8.57 and a beta of 1.97. The business has a 50 day moving average of $73.69 and a 200-day moving average of $65.26.
CRISPR Therapeutics (NASDAQ:CRSP – Get Rating) last posted its quarterly earnings data on Monday, August 8th. The company reported ($2.40) earnings per share for the quarter, missing the consensus estimate of ($2.23) by ($0.17). CRISPR Therapeutics had a negative net margin of 4,274.02% and a negative return on equity of 27.40%. The business had revenue of $0.20 million during the quarter, compared to the consensus estimate of $2.20 million. During the same period in the prior year, the company posted $9.44 earnings per share. The firm’s revenue was down 100.0% compared to the same quarter last year.
Insiders Place Their Bets
In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 25,000 shares of the stock in a transaction on Wednesday, July 27th. The stock was sold at an average price of $75.91, for a total transaction of $1,897,750.00. Following the completion of the transaction, the chief executive officer now directly owns 290,279 shares in the company, valued at $22,035,078.89. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold 75,000 shares of company stock worth $5,108,500 over the last three months. 5.30% of the stock is currently owned by corporate insiders.
Institutional Trading of CRISPR Therapeutics
A number of hedge funds and other institutional investors have recently made changes to their positions in CRSP. Northern Trust Corp increased its stake in shares of CRISPR Therapeutics by 2.4% in the fourth quarter. Northern Trust Corp now owns 43,308 shares of the company’s stock valued at $3,282,000 after buying an additional 1,007 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in shares of CRISPR Therapeutics by 67.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 259,041 shares of the company’s stock valued at $19,636,000 after buying an additional 104,371 shares in the last quarter. BNP Paribas Arbitrage SA increased its stake in shares of CRISPR Therapeutics by 2,074.3% in the fourth quarter. BNP Paribas Arbitrage SA now owns 25,504 shares of the company’s stock valued at $1,933,000 after buying an additional 24,331 shares in the last quarter. Teacher Retirement System of Texas increased its stake in shares of CRISPR Therapeutics by 26.4% in the fourth quarter. Teacher Retirement System of Texas now owns 11,939 shares of the company’s stock valued at $905,000 after buying an additional 2,497 shares in the last quarter. Finally, TD Asset Management Inc. increased its stake in shares of CRISPR Therapeutics by 12.8% in the fourth quarter. TD Asset Management Inc. now owns 34,273 shares of the company’s stock valued at $2,597,000 after buying an additional 3,876 shares in the last quarter. 70.56% of the stock is currently owned by institutional investors and hedge funds.
CRISPR Therapeutics Company Profile
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to email@example.com.
Before you consider CRISPR Therapeutics, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and CRISPR Therapeutics wasn’t on the list.
While CRISPR Therapeutics currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Read more here: Source link